Diffuse large B cell lymphoma other diagnostic studies

	Diffuse large B cell lymphoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Diagnosis
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
CT
MRI
Biopsy
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Diffuse large B cell lymphoma other diagnostic studies On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Diffuse large B cell lymphoma other diagnostic studies All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Diffuse large B cell lymphoma other diagnostic studies
CDC on Diffuse large B cell lymphoma other diagnostic studies
Diffuse large B cell lymphoma other diagnostic studies in the news
Blogs on Diffuse large B cell lymphoma other diagnostic studies
Directions to Hospitals Treating Diffuse large B cell lymphoma
Risk calculators and risk factors for Diffuse large B cell lymphoma other diagnostic studies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sowminya Arikapudi, M.B,B.S. [2]

Overview

Optional procedures include head CT or brain MRI, lumbar puncture to analyze cerebrospinal fluid, and CT or PET-CT scans.

Optional procedures include^[1]

Lumbar puncture
PET-CT scans
MUGA scan is recommended when regimens that contain either anthracyclines or anthracenedione are administered.
echocardiograms is recommended when regimens that contain either anthracyclines or anthracenedione are administered.